MSHO's Annual Review in Hematology 2026

MSHO's Annual Review in Hematology 2026

Join us for an exceptional symposium showcasing the latest breakthroughs in hematology. This premier event brings together professionals from across the cancer care community for an inspiring program focused on innovation, collaboration, and advancing outcomes for patients with blood disorders.

more information

MSHO's Now that the Dust has Settled: Billing & Coding in 2026

MSHO's Now that the Dust has Settled: Billing & Coding in 2026

As we bid farewell to 2025 and welcome 2026, we invite you to join us for a webinar that will explore the updates in the 2026 Medicare Physician Fee Schedule, Outpatient Hospital and Quality Payment Program Final Rules, Quality Programs, and changes from other commercial payers. Don’t miss out on this valuable opportunity!

more information

NCCN Guidelines Updates

NCCN Guidelines Updates

November 12, 2025

NCCN Guidelines Updated for Penile Cancer 
more information

Healthcare Bill Tracking

Track Healthcare Legislation Happening in Michigan!

Updated November 14, 2025

Follow legislation that MSHO is actively monitoring that may impact you and your patients. 

more information

Previous Next

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

As 2025 comes to a close, we extend our heartfelt gratitude to all our members. Your support makes MSHO’s community strong and inspiring. Wishing you a joyful holiday season and a new year full of health, happiness, and memorable moments.

Please note our offices will be closed December 22, 2025, through January 2, 2026.

Christmas 1

Upcoming Events view all events

 December 2025 
SMTWTFS
 123456
78910
111213
14151617181920
21222324252627
28293031   
Sat
24
2026
January 24, 2026

Annual Review in Hematology

7:00 am - 3:00 pm

Dearborn Inn, Dearborn

view event details
Wed
4
2026
February 4, 2026

Now that the Dust has Settled: Billing & Coding in 2026

12:00 pm - 1:00 pm

Webinar

view event details
Wed
4
2026
March 4, 2026

MSHO & WPS Outpatient Hospital Reimbursement

SAVE THE DATE!

Webinar

view event details

Latest News view all news

FDA Approves Johnson & Johnson's RYBREVANT FASPRO amivantamab and hyaluronidase-lpuj for a First-Line Combination Regimen when Combined with LAZCLUZE lazertinib
12/18/2025

FDA Approves Johnson & Johnson's RYBREVANT FASPRO amivantamab and hyaluronidase-lpuj for a First-Line Combination Regimen when Combined with LAZCLUZE lazertinib

FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer
12/15/2025

FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer

FDA Approves Johnson & Johnson's Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-sensitive Prostate Cancer
12/15/2025

FDA Approves Johnson & Johnson's Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-sensitive Prostate Cancer

Oral Chemotherapy Copay and Coinsurance Cap Coming Jan. 1, 2026
11/20/2025

Oral Chemotherapy Copay and Coinsurance Cap Coming Jan. 1, 2026

Blue Cross Blue Shield of Michigan Announcement

Corporate Sponsors view all sponsors